134665-72-8

Usage

Uses

Used in Oncology:
2'-cyano-2'-deoxyarabinofuranosylcytosine is used as an anti-cancer agent for its ability to inhibit DNA replication and induce apoptosis in cancer cells. It is particularly effective against leukemia, lymphoma, and solid tumors, offering a potential treatment option for patients with these conditions.
Used in Combination Therapy:
In the field of oncology, 2'-cyano-2'-deoxyarabinofuranosylcytosine is used as a component of combination therapy to enhance the effectiveness of existing anti-cancer treatments. Its synergistic effects with other drugs can improve outcomes for patients, especially in cases of drug resistance.
Used in Cancer Research:
2'-cyano-2'-deoxyarabinofuranosylcytosine is utilized as a subject of ongoing research in the development of safe and effective cancer treatments. Its unique mechanism of action and potential for combination with other therapies make it a valuable asset in the quest for novel cancer therapies.
Used in Drug Development:
In the pharmaceutical industry, 2'-cyano-2'-deoxyarabinofuranosylcytosine is used as a lead compound in the development of new drugs. Its promising anti-cancer activity and low toxicity profile are being explored to create innovative medications that can offer improved treatment options for cancer patients.

Upstream product

• 135598-72-0 N⁴-acetyl-1-(2-C-cyano-2-deoxy-β-D-arabinofuranosyl)cytosine 
• 135598-71-9 N⁴-acetyl-1-<2-C-cyano-2-deoxy-3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-arabinofuranosyl>cytosine 

Downstream Products

• 71-30-7 Cytosine 
• 135598-68-4 1-(2-cyano-2-deoxy-beta-D-arabinofuranosyl)cytosine 

Relevant academic research and scientific papers

NOVEL STABLE CRYSTAL OF 1-(2'-CYANO-2'-DEOXY-BETA-D-ARABINOFURANOSYL)CYTOSINE MONOHYDROCHLORIDE

Disclosed is a stable crystal of 1-(2′-cyano-2′-deoxy-β-D-arabinofuranosyl)cytosine monohydrochloride. There is provided a crystal of 1-(2′-cyano-2′-deoxy-β-D-arabinofuranosyl)cytosine monohydrochloride having characteristic peaks at 13.7°, 15.7°, 16.0°, 18.6°, 20.3°, and 22.7° as diffraction angles (2θ±0.1°) measured by powder X-ray diffraction, and having a melting point of 192° C. to 197° C.

PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHEIS OF 2'-CYANO-2'-DEOXY-N4-PALMITOYL-1-BETA-D-ARABINOFURANOSYLCYTOSINE

The present invention relates to a process for preparing a compound of formula 682-4, said process comprising the steps of: (i) converting a compound of formula 682-1 into a compound of formula 682-2'; (ii) converting said compound of formula 682-2' into a compound of formula 682-3; and (iii) converting said compound of formula 682-3 into a compound of formula 682-4. Further aspects of the invention relate to the use of the above process in the preparation of 2'-cyano-2'-deoxy-N4 -palmitoyl-1-β-D-arabmofuranosylcytosine, a pyrimidine nucleoside which is therapeutically useful in the treatment and/or prevention of cancer.

INTERMEDIATE AND PROCESSES INVOLVED IN THE PREPARATION OF 2 ' -CYANO-2 ' -DE0XY-N4-PALMIT0YL-1-BETA-ARABIN0FURAN0SYLCYTOSINE

The present invention relates to a process for preparing a compound of formula (682-6'), said process comprising the steps of: formula (682-4), (682-5), (682-6'): (i) converting a compound of formula (682-4) into a compound of formula (682-5); and (ii) converting said compound of formula (682-5) into a compound of formula (682- 6'). Further aspects of the invention relate to the use of the above process in the preparation of 2'-cyano-2'-deoxy-N4-palmitoyl-l-β-D-arabinofuranosylcytosine, a pyrimidine nucleoside which is therapeutically useful in the treatment and/or prevention of cancer.